Search Results for "Growth"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Growth. Results 111 to 120 of 298 total matches.
Abarelix (Plenaxis) for Advanced Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004 (Issue 1178)
— Testosterone and dihydrotestosterone stimulate
growth of all prostatic cells, including malignant cells ...
Abarelix (Plenaxis - Praecis Pharmaceuticals), an injectable gonadotropin-releasing hormone (GnRH) antagonist, has been approved by the FDA for treatment of advanced symptomatic prostate cancer in patients who should not take luteinizing hormone-releasing hormone (LHRH) agonists and who refuse treatment with surgical castration.
Bevacizumab (Avastin) for Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
) is a recombinant
humanized monoclonal antibody that binds to vascular
endothelial growth factor and prevents ...
Bevacizumab (Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting formation of new blood vessels. Previously approved by the FDA for use in combination regimens for first-line treatment of metastatic colon cancer and metastatic non-small cell lung cancer, and used off-label for treatment of agerelated macular degeneration, it has now also been approved by the FDA for use in combination with paclitaxel (Taxol, and others) for first-line treatment of...
Benralizumab (Fasenra) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018 (Issue 1541)
is the major cytokine
responsible for the growth, differentiation, recruitment,
activation, and survival ...
The FDA has approved benralizumab (Fasenra –
AstraZeneca), a humanized monoclonal antibody
selective for the interleukin-5 (IL-5) receptor, for
add-on maintenance treatment of severe asthma in
patients ≥12 years old with an eosinophilic phenotype.
Benralizumab is the third anti-IL-5 antibody to be
approved for treatment of severe eosinophilic asthma;
mepolizumab (Nucala) and reslizumab (Cinqair), which
target IL-5 itself, were approved earlier.
Goserelin - Another LH-RH Analog for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Nov 02, 1990 (Issue 830)
of transient tumor growth secondary to the initial increase in
testosterone and dihydrotestosterone ...
The US Food and Drug Administration recently approved the marketing of goserelin acetate (Zoladex - ICI Pharma), an implant for palliative treatment of advanced prostate cancer. Goserelin acetate is a synthetic decapeptide luteinizing hormone-releasing hormone (LH-RH) analog similar to leuprolide (Lupron; Lupron Depot) (Medical Letter, 27:71, 1985).
Chemotherapy for Esophageal, Gastric and Colorectal Cancers
Treatment Guidelines from The Medical Letter • Aug 01, 2006 (Issue 48)
antibody that
binds to vascular endothelial growth factor (VEGF) and
prevents it from binding ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
St. John's Wort
The Medical Letter on Drugs and Therapeutics • Nov 21, 1997 (Issue 1014)
growth conditions and at
different times of the year.
PHARMACOLOGY — Hypericum extract inhibits uptake ...
Many readers have asked the Medical Letter to evaluate St. John's wort, an herbal extract now widely sold in health food stores and pharmacies, for its effectiveness and safety in the treatment of depression. St. John's wort is licensed in Germany for treatment of anxiety, depression and insomnia. In the USA, it is considered a dietary supplement and has not been evaluated by the FDA.
In Brief: Cabozantinib (Cabometyx) for Advanced Renal Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jul 18, 2016 (Issue 1499)
progressed on antivascular
endothelial growth factor receptor (VEGFR) therapy. In
patients treated ...
The FDA has approved the oral tyrosine kinase inhibitor cabozantinib (Cabometyx – Exelixis) for treatment of patients with advanced renal cell carcinoma previously treated with antiangiogenic therapy. Cabozantinib was first approved in 2012 as Cometriq for treatment of progressive, metastatic medullary thyroid cancer.Anti-VEGF antibodies, tyrosine kinase inhibitors, and mTOR kinase inhibitors have become the standard of care for treatment of unresectable or metastatic renal cell cancer.1FDA approval was based on the results of a randomized open-label trial (METEOR) comparing cabozantinib to...
Ciclesonide (Omnaris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
not
affect growth velocity.
4
PREGNANCY — Ciclesonide is rated category C (risk
cannot be ruled out ...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma
The Medical Letter on Drugs and Therapeutics • Sep 22, 2008 (Issue 1295)
mcg once daily on growth velocity.
5
DOSAGE — The recommended dosage of ciclesonide
is 80-320 mcg ...
The FDA has approved the marketing of the corticosteroid ciclesonide (Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12 years old. Ciclesonide is also available in the US as a nasal spray for allergic rhinitis (Omnaris), and has been available for asthma in Europe since 2003.
Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
levels of HIF may stimulate cancer growth;
use of vadadustat is not recommended in patients
with active ...
The FDA has approved the hypoxia-inducible factor
prolyl hydroxylase inhibitor (HIF-PHI) vadadustat
(Vafseo – Akebia) for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 3 months. Vadadustat is
the second HIF-PHI to be approved in the US for this
indication; daprodustat (Jesduvroq) was approved
earlier, but it was withdrawn from the US market in
2024 for commercial reasons.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):27-9 doi:10.58347/tml.2025.1722b | Show Introduction Hide Introduction